Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is a complex task, with constantly evolving case law and practice on both sides of the Atlantic. In this webinar, AWA’s experts focus on how to create, defend and litigate these patents in Europe and elsewhere.
Patenting Antibody and Cell Therapies – What to Do and What Not to Do
You may also be interested in:
Danish Copyright Act – You may (still) lawfully use copyrighted works for parody purposes
An amendment to the Danish Copyright Act will enter into force on July 1, 2024. The amendment codifies a
Media Vs. Technology – More U.S. Newspapers sue OpenAI and Microsoft
In a significant turn of events, in December 2023, the New York Times took legal action against OpenAI and
Sweden’s Proposed Patents Act
On 11 April 2024, the Swedish Council on Legislation was presented with a new Swedish Patents Act proposal. The